{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.70","value":"719.2"},{"groupId":"OG001","spread":"55.12","value":"840.9"},{"groupId":"OG002","spread":"51.47","value":"782.0"},{"groupId":"OG003","spread":"110.3","value":"1041"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.40","value":"52.89"},{"groupId":"OG001","spread":"52.39","value":"59.23"},{"groupId":"OG002","spread":"49.93","value":"56.20"},{"groupId":"OG003","spread":"81.41","value":"72.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: N-desmethyl selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.84","value":"1101"},{"groupId":"OG001","spread":"56.39","value":"913.1"},{"groupId":"OG002","spread":"51.65","value":"1006"},{"groupId":"OG003","spread":"32.38","value":"1072"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.05","value":"62.06"},{"groupId":"OG001","spread":"45.74","value":"52.90"},{"groupId":"OG002","spread":"42.46","value":"57.46"},{"groupId":"OG003","spread":"39.02","value":"71.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: N-desmethyl selumetinib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"To further evaluate the PK of the granule formulation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"},{"description":"Japan Cohort (\\>=1 to \\<7 years)","id":"OG003","title":"Japan Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 3, 4, 6, 8, 10-12, and 18-24 hours post-dose after selumetinib single dose on the first day of treatment (Cycle 1 Day 1). Pre-dose and 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)","title":"Selumetinib and N-desmethyl Selumetinib BSA Normalised Cmax After Single and Multiple Dose Administration","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"(ng/mL)/m2"}